Departments of Medicine, Queen's University, Kingston, Ontario, Canada.
Departments of Medicine, Queen's University, Kingston, Ontario, Canada; ICES, Queen's University, Kingston, Ontario, Canada.
Am J Kidney Dis. 2022 Jul;80(1):55-64.e1. doi: 10.1053/j.ajkd.2021.09.025. Epub 2021 Nov 20.
RATIONALE & OBJECTIVE: The decision to initiate kidney replacement therapy (KRT) for acute kidney injury (AKI) in cirrhosis remains controversial because it is unclear which patients will benefit. We sought to characterize factors associated with recovery from KRT-treated AKI in patients with cirrhosis to inform shared clinical decision-making.
Population-based retrospective cohort study.
SETTING & PARTICIPANTS: Adult patients from Ontario, Canada, identified using administrative data to have cirrhosis at the time of hospital admission with AKI (based on serum creatinine level) who were treated with KRT (January 1, 2009, to December 31, 2016) and followed up until the end of 2017.
Demographic characteristics and comorbidities before admission.
Kidney recovery defined as the absence of KRT for at least 30 days.
The cumulative incidences of kidney recovery, death, and liver transplant were calculated at 1, 3, 6, and 12 months, and independent predictors of kidney recovery were evaluated using Fine and Gray competing risk regression models that generated subdistribution hazards ratios (sHRs).
Overall, 722 patients were included (median age, 61 [interquartile range, 54-68] years; Model for End-Stage Liver Disease (MELD)-Na score, 26 [interquartile range, 22-34]; 66% were male; 52% had viral hepatitis, 25% nonalcoholic fatty liver disease, 18% alcohol-associated liver disease). The cumulative incidences of kidney recovery at 1, 3, 6, and 12 months were 3%, 22%, 25%, and 26%, respectively. Higher MELD-Na score (sHR per 5 units greater, 0.72 [95% CI, 0.65-0.80]), acute-on-chronic liver failure (sHR, 0.61 [95% CI, 0.43-0.86]), and sepsis (sHR, 0.57 [95% CI, 0.41-0.81]) were associated with a lower hazard of kidney recovery, whereas those on a liver transplant waitlist (sHR, 3.10 [95% CI, 1.96-4.88]) and who were admitted to a teaching hospital (sHR, 1.48 [95% CI, 1.05-2.08]) were more likely to experience kidney recovery.
Observational design, AKI etiology not identified.
Kidney recovery from KRT occurred in only one quarter of patients and was very unlikely after 3 months. These findings provide information regarding prognosis that may guide decisions regarding KRT initiation and continuation.
在肝硬化患者中,关于启动肾脏替代治疗(KRT)治疗急性肾损伤(AKI)的决策仍存在争议,因为尚不清楚哪些患者将从中获益。本研究旨在明确与 KRT 治疗的 AKI 后恢复相关的因素,为临床共同决策提供信息。
基于人群的回顾性队列研究。
利用行政数据,在 2009 年 1 月 1 日至 2016 年 12 月 31 日期间,确定加拿大安大略省在因 AKI(基于血清肌酐水平)入院时患有肝硬化的成年患者,他们接受了 KRT 治疗,并随访至 2017 年底。
入院前的人口统计学特征和合并症。
定义为至少 30 天无 KRT 的肾脏恢复。
计算 1、3、6 和 12 个月时的肾脏恢复、死亡和肝移植的累积发生率,并使用 Fine 和 Gray 竞争风险回归模型评估肾脏恢复的独立预测因素,该模型生成亚分布风险比(sHR)。
共纳入 722 例患者(中位年龄 61 岁[四分位距 54-68];终末期肝病模型钠评分 26[四分位距 22-34];66%为男性;52%患有病毒性肝炎,25%患有非酒精性脂肪性肝病,18%患有酒精相关性肝病)。1、3、6 和 12 个月时肾脏恢复的累积发生率分别为 3%、22%、25%和 26%。更高的终末期肝病模型钠评分(每增加 5 分,风险比 0.72[95%置信区间,0.65-0.80])、慢加急性肝衰竭(风险比 0.61[95%置信区间,0.43-0.86])和脓毒症(风险比 0.57[95%置信区间,0.41-0.81])与肾脏恢复的风险较低相关,而在肝移植等候名单上(风险比 3.10[95%置信区间,1.96-4.88])和入住教学医院(风险比 1.48[95%置信区间,1.05-2.08])的患者更有可能恢复肾脏功能。
观察性设计,未确定 AKI 的病因。
接受 KRT 治疗的患者中仅有四分之一恢复了肾功能,且 3 个月后几乎不可能恢复。这些发现提供了预后信息,可用于指导 KRT 启动和持续治疗的决策。